A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Administration With Marketed Testosterone Products

Testosterone is the principal androgen produced by the male testes. Hypogonadism is the result of inadequate production of testosterone by the Leydig cells of the testes and is reflected by total serum concentrations of testosterone of < 300 nanograms (ng)/deciliters (dL), with discernible diurnal pattern. The etiology of hypogonadism may be primary or secondary. The treatment of males with primary, and in some cases, secondary hypogonadism includes administration of testosterone.

Testim® and Fortesta® are topical gels that when applied daily help to increase the total testosterone levels in the blood through skin absorption. Aveed® is an injectable form of testosterone treatment and participants randomized to this treatment arm will receive 3 injections over the course of 16 weeks.

This study is designed to evaluate the effect on blood pressure of approved testosterone products (Testim®, Fortesta®, and Aveed®) after 16 weeks of therapy using 24-hour ambulatory blood pressure to reveal shifts in blood pressure levels.

Study Overview

• Status: Completed
• Conditions: Hypogonadotropic Hypogonadism; Hypogonadism; Hypogonadism, Male
• Intervention / Treatment: Drug: Aveed Injectable Product; Drug: Fortesta; Drug: Testim

• Study Type: Interventional
• Enrollment (Actual): 676
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Clinical Operations; Phone Number: 800-462-3636; Email: clinicaltrials@endo.com
• Study Contact Backup: Name: Trudy Luxana; Phone Number: 800-462-3636; Email: ClinicalTrials@Endo.com

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35235
      • Endo Clinical Trial Site #8
  • Arizona
    • Tucson, Arizona, United States, 85712
      • Endo Clinical Trial Site #22
  • Arkansas
    • North Little Rock, Arkansas, United States, 72116
      • Endo Clinical Trial Site #15
  • California
    • Bell Gardens, California, United States, 90201
      • Endo Clinical Trial Site #32
    • Canoga Park, California, United States, 91304
      • Endo Clinical Trial Site #33
  • Florida
    • Beverly Hills, Florida, United States, 90211
      • Endo Clinical Trial Site #30
    • Boynton Beach, Florida, United States, 33435
      • Endo Clinical Trial Site #12
    • Boynton Beach, Florida, United States, 33435
      • Endo Clinical Trial Site #34
    • Fleming Island, Florida, United States, 32003
      • Endo Clinical Trial Site #29
    • Miami, Florida, United States, 33014
      • Endo Clinical Trial Site #26
    • Miami, Florida, United States, 33014
      • Endo Clinical Trial Site #2
    • Miami, Florida, United States, 33183
      • Endo Clinical Trial Site #28
    • Miami Beach, Florida, United States, 33140
      • Endo Clinical Trial Site #10
    • Miami Gardens, Florida, United States, 33023
      • Endo Clinical Trial Site #18
    • Oviedo, Florida, United States, 32765
      • Endo Clinical Trial Site #3
    • Pembroke Pines, Florida, United States, 33027
      • Endo Clinical Trial Site #4
    • Pompano Beach, Florida, United States, 33060
      • Endo Clinical Trial Site #11
    • West Palm Beach, Florida, United States, 33401
      • Endo Clinical Trial Site #23
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Endo Clinical Trial Site #16
  • Maryland
    • Glen Burnie, Maryland, United States, 21061
      • Endo Clinical Trial Site #27
    • Towson, Maryland, United States, 21204
      • Endo Clinical Trial Site #17
  • New Jersey
    • East Orange, New Jersey, United States, 07018
      • Endo Clinical Trial Site #35
  • New York
    • Garden City, New York, United States, 11530
      • Endo Clinical Trial Site #9
    • New York, New York, United States, 10016
      • Endo Clinical Trial Site #7
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27103
      • Endo Clinical Trial Site #25
  • Ohio
    • Dayton, Ohio, United States, 45417
      • Endo Clinical Trial Site #5
  • Pennsylvania
    • Bala-Cynwyd, Pennsylvania, United States, 19004
      • Endo Clinical Trial Site #13
  • Texas
    • Houston, Texas, United States, 77036
      • Endo Clinical Trial Site #19
    • Houston, Texas, United States, 77084
      • Endo Clinical Trial Site #31
    • Houston, Texas, United States, 77087
      • Endo Clinical Trial Site #20
    • Missouri City, Texas, United States, 77459
      • Endo Clinical Trial Site #21
    • San Antonio, Texas, United States, 78229
      • Endo Clinical Trial Site #1
  • Vermont
    • Rutland, Vermont, United States, 05701
      • Endo Clinical Trial Site #14
  • Virginia
    • Charlottesville, Virginia, United States, 22911
      • Endo Clinical Trial Site #6
    • Virginia Beach, Virginia, United States, 23462
      • Endo Clinical Trial Site #24

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Have a diagnosis of primary hypogonadism or hypogonadotropic hypogonadism.
2. Have a total serum testosterone at screening < 300 ng/dL based on 2 blood samples obtained at 10 am (+/-2 hours) on 2 separate occasions at least 48 hours apart
3. Be naïve to androgen replacement or washout of 12 weeks following intramuscular androgen injections; 4 weeks following topical or buccal, nasal, or oral androgens.
4. Have a screening blood pressure at rest of less than 140 millimeters of mercury (mm Hg) for systolic blood pressure and less than 90 mm Hg for diastolic blood pressure.
5. Be judged to be in good health.
6. Participants enrolled in the Testim or Fortesta treatment arms: take necessary precautions to avoid skin-to-skin contact and potential transfer and if male use effective contraception.
7. Be willing and able to cooperate with the requirements of the study.

Exclusion Criteria:

1. Is from a vulnerable population, as defined by the US Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board/Independent Ethics Committee (IRB/IEC).
2. Has a history of significant sensitivity or allergy to the study drugs, including androgens, or product excipients.
3. Has a history of or medical examination findings renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric conditions, cardiovascular disease/dysrhythmia) or any other condition(s) that restricts study participation.
4. Has clinically significant changes in any medications (including dosages) or medical conditions in the 28 days prior to screening
5. Is not on a stable medication regimen for at least 3 months for the treatment of a chronic condition.
6. Has had a cardiovascular and/or cerebrovascular event within the last 6 months.
7. Needs blood pressure cuff size larger than 50 centimeters.
8. Works a night shift or performs heavy manual labor.
9. Has any known contraindication(s) to active study treatment including, but not limited to: known or suspected carcinoma of the prostate or breast, previous history of cancer (except basal cell carcinoma of the skin) liver disease, active deep vein thrombosis, atrial fibrillation, untreated sleep apnea, or is immune compromised.

10. Uses known inhibitors (for example, ketoconazole) or inducers of cytochrome P450 3A (for example, dexamethasone, phenytoin, rifampin, carbamazepine) of cytochrome P450 3A (CYP3A) within 30 days prior to study drug administration and through the end of the study.

    1. Uses any of the above listed drugs within 5 half lives of the last dose in the past 6 months prior to study drug administration.
    2. Has received any of the above listed drugs by injection within 30 days or 10 half lives (whichever is longer) prior to study drug administration.
    3. Uses nutraceuticals or homeopathic compounds.
11. Has a history of drug or alcohol abuse within 6 months prior to study drug administration.
12. Has untreated moderate to severe depression.
13. Has any skin lesions/cuts/injury at the application site.
14. Has suspected reversible hypogonadism.
15. Donated blood or blood products or experienced significant blood loss within 90 days prior to study drug administration.
16. Intends to conceive at any time during the study.
17. Donated bone marrow within 6 months prior to study drug administration.
18. Has participated in a previous investigational study or received treatment with an investigational product within 30 days of screening.
19. Has a diagnosis of, is undergoing therapy for, or has received therapy for a hematologic malignancy in the 5 years prior to screening.
20. Has a history of substance abuse or is taking any substance of abuse (Note: participants on a stable dose of any medications that have been prescribed by a healthcare practitioner for a properly documented medical condition are exempt).
21. Abnormal electrocardiogram (ECG) (QT prolongation with QTc ≥450 milliseconds).
22. Has evidence of abnormalities on physical examination, vital signs, ECG, or clinical lab values, unless judged to be clinically insignificant by the investigator
23. Has any other condition that might indicate the participant to be unsuitable for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: AVEED (Testosterone Undecanoate Injection); Fixed dosage level of 750 milligrams (mg)/3 milliliters (mL) administered by intramuscular injections.	Drug: Aveed Injectable Product; Testosterone undecanoate administered by intramuscular injections.; Other Names: Testosterone undecanoate
Active Comparator: FORTESTA (Testosterone Gel); 40 mg once daily topical gel administration.	Drug: Fortesta; Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).; Other Names: Testosterone gel
Active Comparator: TESTIM (Testosterone Gel); 50 mg once daily topical gel administration.	Drug: Testim; Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).; Other Names: Testosterone gel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change from Baseline in 24-Hour Average Systolic Ambulatory Blood Pressure	Baseline (Day 1), Week 16

Secondary Outcome Measures

Outcome Measure	Time Frame
Change from Baseline in 24-Hour Average Arterial Pressure	Baseline (Day 1), Week 16
Change from Baseline in 24-Hour Average Systolic Blood Pressure	Baseline (Day 1), Week 16
Change from Baseline in 24-Hour Average Diastolic Blood Pressure	Baseline (Day 1), Week 16
Change from Baseline in 24-Hour Average Heart Rate	Baseline (Day 1), Week 16
Change from Baseline in 24-Hour Average Pulse Pressure	Baseline (Day 1), Week 16
Percent of Participants Taking New Antihypertensive Medications	Week 16
Percent of Participants with Dose Increases From Baseline in Antihypertensive Medications	Week 16

Collaborators and Investigators

• Sponsor: Endo Pharmaceuticals
• Investigators: Study Director: Karen Kang, Endo Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2020
• Primary Completion (Actual): July 12, 2023
• Study Completion (Actual): July 12, 2023

Study Registration Dates

• First Submitted: June 30, 2020
• First Submitted That Met QC Criteria: June 30, 2020
• First Posted (Actual): July 2, 2020

Study Record Updates

• Last Update Posted (Actual): August 1, 2023
• Last Update Submitted That Met QC Criteria: July 27, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Gonadal Disorders; Hypogonadism; Eunuchism; Physiological Effects of Drugs; Antineoplastic Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Androgens; Anabolic Agents; Testosterone; Methyltestosterone; Testosterone undecanoate; Testosterone enanthate; Testosterone 17 beta-cypionate
• Other Study ID Numbers: EN3000-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No